Equibles does not estimate personal net worth.
Get an email with a short summary when Inovio Pharmaceuticals, Inc. publishes a filing, an earnings call transcript or a press release.
Get INO alertsPeter Kies is recorded as CFO at Inovio Pharmaceuticals, Inc. (INO). Peter Kies has spoken on 23 earnings calls across 1 company, most recently for Inovio Pharmaceuticals, Inc. on August 12, 2026. Inovio Pharmaceuticals, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Inovio Pharmaceuticals, Inc. includes Jacqueline E. Shea (CEO, COO and Board Member), Jacqueline Shea (CEO, COO and Board Member), Simon X. Benito (Chairman and Board Member) and 7 others.
“Today, I'd like to provide an overview of Inovio's financial results for the second quarter of 2026. As Jackie noted, our primary goal is to advance INO 3107 towards approval and to enable an efficient launch, if approved.”
“Today I'd like to provide an overview of Inovio's financial results for the first quarter of 2026. As Jackie noted, our primary goal is to advance INO 3107 towards approval, and we remain focused on optimizing resources to support that program.”
“Today, I'd like to provide an overview of Inovio's financial results for the third quarter of 2025 and provide a snapshot of the year so far.”
“Today I'd like to provide an overview of Inovio's financial results for the first quarter 2025. As Jacqui mentioned, we're focusing resources on advancing our lead candidate 3107 and our other strategic priorities.”
“Today, I'd like to provide an overview of Inovio's financial results for the fourth quarter and full year of 2024.”
Biotechnology · Healthcare
CFO
